Literature DB >> 34623224

Is there a difference in the efficacy of COVID-19 vaccine in males and females? - A systematic review and meta-analysis.

Zheng Zhu1, Lizhen Xu1, Gang Chen1,2,3.   

Abstract

INTRODUCTION: Females generally have higher antibody responses to viral vaccines. Our objectives were to compare gender differences in the efficacy of COVID-19 vaccination.
METHODS: Data sources: Studies from PubMed, Embase, Cochrane Central Register, Web of Science, ClinicalTrials.gov, and the World Health Organization's International Clinical Trials Registry Platform.
RESULTS: We included four eligible trials; all were categorized as having a low risk of bias. COVID-19 vaccine was significantly effective in both males and females. Slightly more SARS-CoV-2 infections were recorded in females than in males, but the difference was not significant (RR 1.064 [0.888-1.274]; p = .502, I2 = 5.7%; p = .367, 643,127 participants).
CONCLUSION: Despite significant biological and behavioral differences between males and females, we found no significant gender differences in the efficacy of the COVID-19 vaccines, especially in younger populations. Further pragmatic trials are needed to confirm the gender differences in protective response of different types of vaccines to different age groups.

Entities:  

Keywords:  COVID-19 vaccine; efficacy; sex

Mesh:

Substances:

Year:  2021        PMID: 34623224      PMCID: PMC8903917          DOI: 10.1080/21645515.2021.1984135

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  19 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis.

Authors:  Lizhen Xu; Yaqian Mao; Gang Chen
Journal:  Aging (Albany NY)       Date:  2020-06-23       Impact factor: 5.682

3.  Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?

Authors:  Catharine Chambers; Danuta M Skowronski; Caren Rose; Gaston De Serres; Anne-Luise Winter; James A Dickinson; Agatha Jassem; Jonathan B Gubbay; Kevin Fonseca; Steven J Drews; Hugues Charest; Christine Martineau; Martin Petric; Mel Krajden
Journal:  Open Forum Infect Dis       Date:  2018-09-04       Impact factor: 3.835

4.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

5.  Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.

Authors:  Denis Y Logunov; Inna V Dolzhikova; Dmitry V Shcheblyakov; Amir I Tukhvatulin; Olga V Zubkova; Alina S Dzharullaeva; Anna V Kovyrshina; Nadezhda L Lubenets; Daria M Grousova; Alina S Erokhova; Andrei G Botikov; Fatima M Izhaeva; Olga Popova; Tatiana A Ozharovskaya; Ilias B Esmagambetov; Irina A Favorskaya; Denis I Zrelkin; Daria V Voronina; Dmitry N Shcherbinin; Alexander S Semikhin; Yana V Simakova; Elizaveta A Tokarskaya; Daria A Egorova; Maksim M Shmarov; Natalia A Nikitenko; Vladimir A Gushchin; Elena A Smolyarchuk; Sergey K Zyryanov; Sergei V Borisevich; Boris S Naroditsky; Alexander L Gintsburg
Journal:  Lancet       Date:  2021-02-02       Impact factor: 79.321

6.  Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2.

Authors:  Yuanyuan Qiao; Xiao-Ming Wang; Rahul Mannan; Sethuramasundaram Pitchiaya; Yuping Zhang; Jesse W Wotring; Lanbo Xiao; Dan R Robinson; Yi-Mi Wu; Jean Ching-Yi Tien; Xuhong Cao; Stephanie A Simko; Ingrid J Apel; Pushpinder Bawa; Steven Kregel; Sathiya P Narayanan; Gregory Raskind; Stephanie J Ellison; Abhijit Parolia; Sylvia Zelenka-Wang; Lisa McMurry; Fengyun Su; Rui Wang; Yunhui Cheng; Andrew D Delekta; Zejie Mei; Carla D Pretto; Shaomeng Wang; Rohit Mehra; Jonathan Z Sexton; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-11       Impact factor: 11.205

7.  Sex-disaggregated data in COVID-19 vaccine trials.

Authors:  Lavanya Vijayasingham; Evelyne Bischof; Jeannette Wolfe
Journal:  Lancet       Date:  2021-03-05       Impact factor: 79.321

8.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Authors:  Noa Dagan; Noam Barda; Eldad Kepten; Oren Miron; Shay Perchik; Mark A Katz; Miguel A Hernán; Marc Lipsitch; Ben Reis; Ran D Balicer
Journal:  N Engl J Med       Date:  2021-02-24       Impact factor: 91.245

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

10.  Sex differences in immune responses that underlie COVID-19 disease outcomes.

Authors:  Takehiro Takahashi; Mallory K Ellingson; Patrick Wong; Benjamin Israelow; Carolina Lucas; Jon Klein; Julio Silva; Tianyang Mao; Ji Eun Oh; Maria Tokuyama; Peiwen Lu; Arvind Venkataraman; Annsea Park; Feimei Liu; Amit Meir; Jonathan Sun; Eric Y Wang; Arnau Casanovas-Massana; Anne L Wyllie; Chantal B F Vogels; Rebecca Earnest; Sarah Lapidus; Isabel M Ott; Adam J Moore; Albert Shaw; John B Fournier; Camila D Odio; Shelli Farhadian; Charles Dela Cruz; Nathan D Grubaugh; Wade L Schulz; Aaron M Ring; Albert I Ko; Saad B Omer; Akiko Iwasaki
Journal:  Nature       Date:  2020-08-26       Impact factor: 49.962

View more
  3 in total

1.  Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study.

Authors:  Lucian-Ion Giubelan; Florentina Dumitrescu; Livia Dragonu; Andreea Cristina Stoian; Cristina Ilie; Ilona Stanciu
Journal:  Curr Health Sci J       Date:  2022-03-31

2.  Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.

Authors:  Valéria Valim; Olindo Assis Martins-Filho; Maria da Penha Gomes Gouvea; Luiz Antônio Bastos Camacho; Daniel Antunes Maciel Villela; Sheila Maria Barbosa de Lima; Adriana Souza Azevedo; Lauro Ferreira Pinto Neto; Carla Magda Allan Santos Domingues; Nésio Fernandes de Medeiros Junior; Isac Ribeiro Moulaz; Laiza Hombre Dias; Samira Tatiyama Miyamoto; Andréa Teixeira-Carvalho; José Geraldo Mill
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

3.  Choosing between Homologous or Heterologous COVID-19 Vaccination Regimens: A Cross-Sectional Study among the General Population in Italy.

Authors:  Marco Clari; Alessandro Godono; Beatrice Albanesi; Elena Casabona; Rosanna Irene Comoretto; Ihab Mansour; Alessio Conti; Valerio Dimonte; Catalina Ciocan
Journal:  Int J Environ Res Public Health       Date:  2022-03-03       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.